OARS funding Cancer

The Salisbury Award Competition is designed for translational cancer research projects that are formally and verifiably associated with promising scientific discoveries described in the application and that are either within universities, research hospitals, cancer centers, other such laboratories or start-up companies. Submissions by principal investigators of projects with viable clinical trial approval prospects and whose intellectual property has not yet been licensed or acquired by parties outside of the applying institution are especially encouraged.

The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

The research that we fund is vital to our mission of understanding the role of diet, nutrition, body composition and physical activity in reducing cancer risk and improving outcomes for cancer patients and survivors. Our Research Grant Program builds on and is informed by the scientific findings from our Continuous Update Project and Third Expert Report.

Elsa Uhinck Pardee was born on a farm south of Cleveland, Ohio, on November 7, 1884, and received her elementary education in a one-room school. She married James T. Pardee in 1914. A college classmate of Herbert H. Dow, Mr. Pardee was a founder and board member of the Dow Chemical Company. Before her death from breast cancer in 1944 at the age of 59, Elsa directed that $1 million in Dow stock be devoted to the "control and cure of cancer." The Elsa U. Pardee Foundation was formed in memory of Elsa by the family she left behind.

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.

The Rivkin Center is announcing funds for Scientific Scholar Awards to be allocated based on scientific merit. Scientific Scholar Awards are intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. The two-year awards will provide a total of $120,000 in funding.

The Desmoid Tumor Research Foundation, Inc. ("DTRF") funds research that will advance the current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure. DTRF is the only foundation in the country dedicated to facilitating and funding research for a cure for desmoid tumors. We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research. Research proposals with additional sources of funding support are particularly desirable. Researchers must be willing to collaborate with other scientists and institutions with similar interests.

The COVID-19 pandemic is having a significant impact on cancer patients and survivors. Access to cancer prevention and screening services may be limited or unavailable due to the pandemic. To help address these issues and find solutions, the CARE Fund seeks to support research that focuses on the impact of COVID-19 on outcomes, research, risks, or well-being for cancer patients.

The THRIVE grant program is designed to provide seed funding for clinical and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. Awards are made to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions.

The Rivkin Center is announcing funds for Pilot Study Awards to be allocated based on scientific merit. Pilot Study Awards support investigator-initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered. The two-year awards will provide a total of $75,000 in funding, with the possibility of an additional $25,000 awarded in year two, upon evaluation of year one progress, contingent on availability of funds.

The Melanoma Research Alliance (MRA) is pleased to announce the Second Release of its Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.  The 2020 - 2021 award cycle, is anticipated to support at least $7.6 million in new funding. Proposals will be accepted for Established Investigator, Academic-Industry Partnership, Young Investigator, and Pilot Awards.  This Second Release includes two new Special Opportunity awards focused on Melanoma Brain Metastasis, in partnership with the Rising Tide Foundation for Clinical Cancer Research. Other Special Opportunities include: Pediatric Melanoma Young Investigator Award with St. Baldrick's Foundation, UK or Israel-Based Young Investigator Award with Rosetrees Trust, Radiation Oncology Young Investigator Award with ASTRO (U.S. applicants only), and Immunotherapy Young Investigator Awards supported by Bristol Myers Squibb (BMS).

The St. Baldrick's Foundation works hard to be sure that every dollar makes the biggest impact possible in childhood cancer research. The Foundation has held several Research Priorities Summits with many of the country's leading pediatric oncology researchers participating to advise the staff and board of directors on funding priorities. The St. Baldrick's team and Scientific Advisors meet regularly to be sure St. Baldrick's funds make the greatest impact on pediatric cancer research. Current funding priorities are divided into four categories: * New discovery research * Translational research and early phase clinical trials * Phase III clinical trials & infrastructure support of participating institutions (primarily the fall grant cycle) * Education of new pediatric oncology researchers In addition to research to understand the biology of childhood cancers and discover leads to more effective treatments, topics of interest include, but are not limited to: * Adolescents & young adults * Survivorship, outcomes, and quality of life * Supportive care * Epidemiology and pediatric cancer predispositions * Precision medicine * Alternative & complementary therapies

A. Noam Chomsky Global Connections Awards celebrate the power of human connections. The awards recognize distinguished service to the global mission of the STAR Scholars Network. Several individuals with a deep impact on advancing global, social mobility are recognized every year. We live in a time when innovation and creativity in support of humanity are of great importance. The Star Scholars Network recognizes the commitment of concerned people able and willing to make a difference in the lives of others. Nominations for this award are solicited from around the world. The nominee can be from any field. Beginning in 2020, the Star Scholars Network is committed to promoting transnational research, or collaborative research between scholars of two or more countries (e.g., joint publications, research partnerships, etc.). The Global Connections Awards recognize STAR Scholars for their achievements and distinctive contributions to translational research that demonstrates the very best of scholarly collaboration among scholars around the world. In December 2020, the Star Scholars Network will provide awards in three categories: North Star Medal of Lifetime Achievement, Shining Star Achievement in Research Award, Rising Star Emerging Scholar Certificate

The Ohio Department of Higher Education (ODHE) will make strategic investments to support expanded opportunities for students in Science, Technology, Engineering, Mathematics and Medical (STEMM) fields. The investments will directly impact the ability of the state of Ohio to educate and train students to meet Ohio's career and job opportunities today and tomorrow. Choose Ohio First provides scholarships to students in innovative academic programs developed by Ohio's two-year and four-year, public and private colleges and universities, along with their business partners. The scholarships connect students to work-based learning experiences and careers in STEMM fields in order to recruit and retain these students in Ohio. Choose Ohio First is part of a strategic effort to deepen Ohio's economic strength by increasing the talent pipeline for STEMM-related industries, including computer science, through degree and certificate completion.

The American Cancer Society and Pfizer Global Medical Grants are collaborating to offer a new competitive grant opportunity focused on addressing systemic race-related barriers that contribute to disparities in outcomes among Black men and women with cancer.

LIVESTRONG Cancer Institutes' mission: To rethink the full range of cancer care, from prevention to diagnosis, treatment, survivorship and end-of-life care - all with a focus on the patient's needs, values and preferences. Projects and organizations funded must also directly support the LIVESTRONG mission and the mission of the LIVESTRONG Cancer Institutes and should not be at odds with either mission.

Join BioOhio and the Columbus chapter of the Healthcare Businesswomen's Association (HBA) for a FREE online event - our second Diversity in Bioscience & Healthcare event of 2020, on August 20 at 5 pm. The engaging discussion focuses on the importance of supporting STEM programming at an early age within under-represented communities to encourage careers within the science and healthcare industries. Our special guests include: Frederic Bertley, Ph.D., President & CEO, COSI Kirsten M. Ellenbogen, Ph.D., President & CEO, Great Lakes Science Center Kelly Lewis, Bioscience Technologies Program Instructor, Eastland-Fairfield Career and Technical Schools Lead by the talented Brooke Cartus, Director of Business Development and Senior Facilitator, ImprovEdge! Featuring networking opportunities during the event! This discussion will be held via Zoom. Login instructions are included in your registration confirmation email and reminder emails sent before the event. BioOhio and the Healthcare Business Women's Association (HBA) support all efforts to increase diversity and inclusion within the bioscience and healthcare industries and invite you to join us for our next discussion, Overcoming Obstacles in the Workplace: Making Work Accessible on November 14th, 2020. This event is brought to you by BioOhio in partnership with the Columbus chapter of the Healthcare Businesswomen's Association (HBA) and is made possible by the generous support of BioOhio members AtriCure and BIO.

Applications will be accepted for a broad range of melanoma research projects involving basic science, clinical trials, etc. 1. An adequate discussion of biostatistics is required, including but not limited to specification of numbers of cell lines, laboratory animals, or patients to be treated in the studies. 2. Plans for adjustment for multiple looks should be presented, particularly in regards to clinical endpoints and evaluation of multiple biomarkers.

The objective of this AGA Research Foundation award is to support an established investigator in the field of gastric cancer research working to enhance our fundamental understanding of gastric cancer pathobiology or approaches to prevent, treat or cure gastric cancer.

The objective of this AGA Research Foundation award is to provide supplemental funding to early career investigators who have existing career development awards and are conducting research relevant to the pathogenesis, prevention, diagnosis or treatment of digestive cancer.